Matthew E. Korenberg - Jun 28, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: President & Chief Operating
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Stock symbol: LGND
Transactions as of: Jun 28, 2024
Transactions value $: $21,247
Form type: 4
Date filed: 7/2/2024, 07:45 PM
Previous filing: May 15, 2024
Next filing: Aug 13, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Other	$21.2K	+350	+0.41%	$60.71	86.6K	Jun 28, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).